Honma M, Tamura G, Shirato K, Takishima T
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Thorax. 1994 Jul;49(7):649-51. doi: 10.1136/thx.49.7.649.
A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. To investigate the mechanism of action of auranofin the bronchial responsiveness to inhaled methacholine has been studied in well controlled asthmatic subjects.
Nineteen adult asymptomatic asthmatic subjects received auranofin (3 mg orally twice a day) or inactive placebo in random order for 12 weeks in a double blind fashion. Bronchial responsiveness to inhaled methacholine and pulmonary function tests were measured at the same time on different days before, and six and 12 weeks after, each treatment.
Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin was decreased compared with that before treatment with auranofin and 12 weeks after treatment with inactive placebo, although the treatment did not improve pulmonary function tests.
Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin is decreased in a group of mild asymptomatic asthmatic patients with normal lung function.
日本最近一项双盲临床试验表明，金诺芬（6毫克/天）对中度至重度哮喘患者是一种有效的治疗方法。为了研究金诺芬的作用机制，对病情得到良好控制的哮喘患者的支气管对吸入乙酰甲胆碱的反应性进行了研究。
19名成年无症状哮喘患者以双盲方式随机接受金诺芬（口服3毫克，每日两次）或无活性安慰剂治疗，为期12周。在每次治疗前、治疗6周和12周后的不同日期同时测量支气管对吸入乙酰甲胆碱的反应性和肺功能测试。
与金诺芬治疗前和无活性安慰剂治疗12周后相比，金诺芬治疗12周后非特异性支气管高反应性降低，尽管该治疗未改善肺功能测试结果。
在一组肺功能正常的轻度无症状哮喘患者中，金诺芬治疗12周后非特异性支气管高反应性降低。
